NeuroSense has secured Brazilian Patent No. BR 112024007727-6 for its PrimeC composition, which combines ciprofloxacin and celecoxib in a unique synchronized formulation. This patent, valid until October 2042, follows similar approvals in the U.S. and Australia, bolstering NeuroSense’s global intellectual property portfolio. The distinct formulation of PrimeC is designed to enhance therapeutic efficacy beyond simple co-administration of the two drugs.

The significance of this development lies in its potential applications for Amyotrophic Lateral Sclerosis (ALS) and other neurodegenerative diseases. Following positive results from the Phase 2b PARADIGM trial, NeuroSense is poised to launch a Phase 3 pivotal trial (PARAGON) for PrimeC, with FDA clearance already in hand. The combination of ciprofloxacin, an antibiotic with neuroprotective properties, and celecoxib, a non-steroidal anti-inflammatory drug (NSAID), may offer a novel therapeutic approach to modulate neuroinflammation and oxidative stress, both critical factors in neurodegeneration.

This patent grant not only solidifies NeuroSense’s position in the competitive landscape of neurodegenerative disease treatments but also underscores a shift towards combination therapies that leverage existing drugs in innovative ways. As researchers continue to explore the complex mechanisms underlying aging and neurodegeneration, PrimeC could represent a pivotal step in enhancing healthspan and addressing unmet medical needs in ALS and potentially other conditions. The implications for drug development timelines are significant, as the successful transition from Phase 2 to Phase 3 trials could expedite the path to market for this promising therapy.

Source: longevity.technology